TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1326846
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMWH) 2500 anti‐XaU once daily
Study: 1326846
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UH) 5000 anti‐XaU twice daily
Study: 3890130
Drug: L-carnitine, 2
Normalized name: L-Carnitine, 250 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine, 2 g i.v. three times a week
Study: 24607003
Drug: Investigational vaccine
Normalized name: INVESTIGATIONAL VACCINES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational vaccine formulations containing dPly alone (10 or 30 μg) or both dPly and PhtD (10 or 30 μg each)
Study: 11850760
Drug: Single drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single drugs (amphetamine, benzphetamine, fenfluramine, sibutramine)
Study: 11850760
Drug: Combination drugs
Normalized name: combination drugs used in erectile dysfunction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination drugs
Study: 11850760
Drug: Overall medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall medications studied
Study: 3530226
Drug: Semisynthetic human
Normalized name: INSULIN,NPH,HUMAN/SEMISYNTHETIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semisynthetic human insulin (Novo)
Study: 3530226
Drug: Highly purified
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highly purified porcine insulin (Monocomponent)
Study: 28972854
Drug: 500 mL
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mL of milk (MILK)
Study: 10958249
Drug: Bromocriptine 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine 1.25 mg
Study: 12655514
Drug: One course
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One course of perioperative chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil
Study: 7744132
Drug: Nimesulide 50
Normalized name: nimesulide 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimesulide 50 mg bd
Study: 2661700
Drug: Ticlopidine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine (250 mg twice per day)
Study: 1097490
Drug: Gerovital H3
Normalized name: Vitamin H3
DrugBank: Procaine (DB00721)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gerovital H3 (5 ml injection, 3 times a week for first 6 weeks, then 10 ml injection for next 6 weeks)
Study: 28916443
Drug: AQ-13 (638.50
Approvals — FDA: no, EMA: no, PMDA: no
Description: AQ-13 (638.50 mg on days 1 and 2, 319.25 mg on day 3)
Study: 28916443
Drug: Artemether plus
Normalized name: Artemether
DrugBank: Artemether (DB06697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Artemether plus lumefantrine (80 mg artemether and 480 mg lumefantrine twice daily for 3 days)
Study: 17935647
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron supplements (control)
Study: 23574579
Drug: LMWH followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LMWH followed by warfarin
Study: 18942523
Drug: LMWH as
Approvals — FDA: no, EMA: no, PMDA: no
Description: LMWH as a bridge therapy
Study: 14555312
Drug: Certoparin (fixed,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Certoparin (fixed, body-weight-independent dose of 8,000 IU b.i.d. for 8.6 days)
Study: 14555312
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (IV, adjusted to an 1.5 to 3.0-fold prolongation of the aPTT for 12.0 days)
Study: 10703934
Drug: HRT group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT group (n = 145) received a sequential combination of 2 mg estradiol valerate and 1 mg CPA with or without vitamin D3, 100‐300 IU + 500 mg calcium lactate/day (equal to 93 mg Ca2+)
Study: 10703934
Drug: Non-HRT group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-HRT group (n = 177) received calcium lactate, 500 mg alone or in combination with vitamin D3, 100‐300 IU/day
Study: 8356542
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of methohexital
Study: 22928495
Drug: Guaiazulene (GA)
Normalized name: guaiazulene
DrugBank: Guaiazulen (DB13329)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guaiazulene (GA) containing local pomade (0.05 g/100 g)
Study: 22928495
Drug: Extended antifungal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended antifungal treatment (Control)
Study: 20200165
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for silent GERD
Study: 16373898
Drug: 20 mg/day
Normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/day ranirestat
Study: 16373898
Drug: 5 mg/day
Normalized name: Lyllana 0.05 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/day ranirestat
Study: 10926393
Drug: Alcoholic-hand-gel regimen
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcoholic-hand-gel regimen
Study: 1997044
Drug: Morphine sulphate
Normalized name: Morphine sulphate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine sulphate 120 micrograms kg‐1
Study: 29848335
Drug: Life skills
Normalized name: Life-O-Gen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Life skills building education and multiple micronutrient supplementation (UNIMMAP composition), provided bi-monthly and twice-weekly respectively.
Study: 24496740
Drug: Cost analysis
Normalized name: Chemicals and reagents for analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cost analysis of disposable spray tips
Study: 19619690
Drug: 4 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g/d prescription omega-3-acid ethyl esters (P-OM3)
Study: 23098346
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg / Hydrochlorothiazide 12.5 mg
Study: 23098346
Drug: Losartan 100
Normalized name: LOSARTAN 100MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 100 mg / Hydrochlorothiazide 25 mg
Study: 1608850
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg phenytoin
Study: 1608850
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg phenytoin
Study: 28668573
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of whole-virus H7N9 vaccine (30μg HA with aluminum hydroxide adjuvant)
Study: 28668573
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of whole-virus H7N9 vaccine (15μg HA)
Study: 28668573
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of whole-virus H7N9 vaccine (30μg HA without adjuvant)
Study: 12641688
Drug: Tramadol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (1 mg.kg(‐1))
Study: 2941291
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg ciprofloxacin (n = 85)
Study: 26892847
Drug: Mindfulness-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based cognitive therapy (MBCT) with discontinuation of mADM (n=128)
Study: 26892847
Drug: Mindfulness-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based cognitive therapy (MBCT) + maintenance antidepressant medication (mADM) (n=121)
Study: 20129568
Drug: RIPC and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: RIPC and morphine
Study: 16868056
Drug: Behavioral intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Behavioral intervention promoting a diet with 28% energy from total fat, less than 8% from saturated fat, 9% or less from polyunsaturated fat, and less than 75 mg cholesterol per 1000 kcal.
Study: 10856147
Drug: Inhaled indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled indomethacin (50 mg/d)
Study: 9126694
Drug: Meropenem (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem (1,000 mg iv every 8 hours)
Study: 9126694
Drug: Clindamycin (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin (900 mg every 8 hours) plus Tobramycin (5 mg/[kg.d] in three divided doses) iv
Study: 1493841
Drug: Temazepam (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temazepam (15 mg) plus ethanol (peak blood concentration of 11 mmol.l‐1)
Study: 6861846
Drug: Nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20 mg p.o.)
Study: 18520792
Drug: Schedule-dependent low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Schedule-dependent low-dose paclitaxel for radiosensitization
Study: 12790886
Drug: Surgical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical therapy (anteromesial temporal lobe resection)
Study: 10348786
Drug: AZ (5
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AZ (5 mg/kg/day) alone (ALONE)
Study: 10348786
Drug: AZ (5
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AZ (5 mg/kg/day) and ATQ (30 mg/kg/day) simultaneously (SIM)
Study: 7554041
Drug: Oral tamoxifen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tamoxifen at 10 mg twice a day
Study: 7554041
Drug: Percutaneous 4-OH-TAM
Normalized name: 4-OH-A
DrugBank: Formestane (DB08905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous 4-OH-TAM at 0.5 mg/day
Study: 7554041
Drug: Percutaneous 4-OH-TAM
Normalized name: 4-OH-A
DrugBank: Formestane (DB08905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous 4-OH-TAM at 1 mg/day
Study: 7554041
Drug: Percutaneous 4-OH-TAM
Normalized name: 4-OH-A
DrugBank: Formestane (DB08905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous 4-OH-TAM at 1 mg/day to a large cutaneous area excluding the breasts
Study: 7554041
Drug: Percutaneous 4-OH-TAM
Normalized name: 4-OH-A
DrugBank: Formestane (DB08905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous 4-OH-TAM at 2 mg/day to a large skin area excluding the breasts
Study: 30045346
Drug: 12 months
Normalized name: Elecare HMO 0-12 Months
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 months of anti tubercular therapy (ATT)
Study: 2523665
Drug: Isradipine (1.25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine (1.25, 2.5, and 5.0 mg twice daily)
Study: 66240
Drug: Oral oxymorphone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral oxymorphone
Study: 67128
Drug: Intramuscular oxymorphone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular oxymorphone
Study: 6730874
Drug: Intramuscular morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular morphine
Study: 31350753
Drug: Placebo beverage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo beverage (PB) - kCal: 5, Na: 35 mg
Study: 9549168
Drug: Doxazosin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin (4 mg daily)
Study: 7522395
Drug: G-CSF 10
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF 10 micrograms/kg
Study: 7522395
Drug: G-CSF 5
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF 5 micrograms/kg
Study: 3139705
Drug: Control preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control preparation containing polysaccharides only (24 volunteers)
Study: 29265454
Drug: Non-surgical periodontal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical periodontal treatment (oral hygiene instructions + scaling and root planing using ultrasound and Gracey curettes)
Study: 29265454
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (oral hygiene instructions + supragingival removal of plaque and calculus using ultrasound)
Study: 27569442
Drug: MAP (cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAP (cisplatin 120 mg/m2, doxorubicin 37.5 mg/m2 on days 1 and 2, high-dose methotrexate 12 g/m2)
Study: 25405132
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg elemental magnesium (as magnesium sulfate ‐MgSo4‐) daily for 3 months
Study: 19083405
Drug: Creatine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine (4 g/d for 2 years)
Study: 14560218
Drug: Aspirin (ASA)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (ASA) 325 mg daily
Study: 14560218
Drug: Clopidogrel (Clop)
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clopidogrel (Clop) 75 mg daily
Study: 14560218
Drug: Cilostazol (Cilo)
Normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cilostazol (Cilo) 100 mg twice daily
Study: 8215478
Drug: Granisetron plus
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granisetron plus hydroxyzine hydrochloride (Group G/H)
Study: 8215478
Drug: Granisetron alone
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granisetron alone (Group G)
Study: 3691592
Drug: Nicardipine (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine (90 mg/day) + Propranolol (120 mg/day)
Study: 6469425
Drug: Propranolol (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (120 mg/day)
Study: 17022378
Drug: Pycnogenol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pycnogenol (50 mg capsules, 3 times daily for a total of 150 mg daily for 4 weeks)
Study: 17067979
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no treatment during the observation period)
Study: 14672470
Drug: Intravenous ampicillin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ampicillin, 2 g every 6 hours, and gentamicin, 1.5 mg/kg every 8 hours, continued until afebrile and asymptomatic for 24 hours (control group)
Study: 10723818
Drug: Nicotine oral
Normalized name: nicotine Oral Lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine oral inhaler
Study: 27884360
Drug: Drug-Coated Balloon
Normalized name: CATHETER,BALLOON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-Coated Balloon (DCB) angioplasty
Study: 26689885
Drug: Subcutaneous unfractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous unfractionated heparin 5000 units three-times a day
Study: 26689885
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion of unfractionated heparin 625 IU/h
Study: 22525915
Drug: Paracervical block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracervical block (2 mL 1% buffered lidocaine at tenaculum site + 18 mL at four sites)
Study: 22525915
Drug: Sham (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham (no injection)
Study: 18377682
Drug: FOS (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOS (10 g once daily for 5 weeks)
Study: 18377682
Drug: Maltodextrin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maltodextrin (10 g once daily for 2 weeks during run-in phase)
Study: 14708414
Drug: Acetaminophen (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (20 mg/kg) administered rectally if pain score > 3/10
Study: 3552358
Drug: Verapamil (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (450 +/- 30 mg/day)
Study: 29401192
Drug: Multi-ingredient preworkout
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-ingredient preworkout supplement (SUP)
Study: 9144347
Drug: TIB, tibolone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIB, tibolone, 2.5 mg/day continuously, orally
Study: 9144347
Drug: PO, peroral
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO, peroral E2, 2 mg/day continuously, plus sequential oral dydrogesterone (DYD), 10 mg/day, for 14 days of a 28-day cycle
Study: 3979761
Drug: Clear liquid
Normalized name: Ensure Clear Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clear liquid diet with evening-laxative and morning-enema regimen
Study: 21367884
Drug: Germinated barley
Approvals — FDA: no, EMA: no, PMDA: no
Description: Germinated barley foodstuff (GBF), 30 g daily for two months along with standard drug therapy
Study: 28233343
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment groups (Computerized brain fitness exercise and Memory support system)
Study: 25909969
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of oxytocin (30 IU in 0.9% normal saline/500 ml)
Study: 9574640
Drug: 5% albumin
Normalized name: Flexbumin 5% Albumin (Human) Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% albumin solution (hypervolemia group, n = 19)
Study: 9574640
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline solution + 5% albumin solution (normovolemia group, n = 24)
Study: 9574640
Drug: 5% albumin
Normalized name: Flexbumin 5% Albumin (Human) Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% albumin solution (hypervolemia group)
Study: 2971597
Drug: CAF plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAF plus Provera 200 mg daily for 3 weeks followed cyclically by Tamoxifen 20 mg daily for 3 weeks
Study: 20523113
Drug: HB‐AS02 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: HB‐AS02 vaccine (0 and 1 month)
Study: 9504193
Drug: Lysine Clonixinate
Normalized name: lysine clonixinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lysine Clonixinate (LC) 125 mg
Study: 9504193
Drug: Paracetamol 500
Normalized name: Paracetamol 500 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 500 mg + Codeine 30 mg
Study: 8306757
Drug: 22-mg transdermal
Normalized name: methylphenidate 2.22 MG/HR Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 22-mg transdermal nicotine therapy with group counseling for 8 weeks (study 1)
Study: 8306757
Drug: 22-mg transdermal
Normalized name: methylphenidate 2.22 MG/HR Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 22-mg transdermal nicotine therapy for 4 weeks followed by 11-mg for 2 weeks with brief individual counseling (study 2)
Study: 29847967
Drug: Intranasal saline,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal saline, intravenous saline and propofol (group P)
Study: 29847967
Drug: Intranasal saline,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal saline, intravenous sulfentanil and propofol (group SP)
Study: 18566196
Drug: Gabapentin 1200
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin 1200 mg po (Group G)
Study: 12757969
Drug: Desipramine (DMI)
DrugBank: Desipramine (DB01151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desipramine (DMI) 150 mg/day
Study: 10680303
Drug: Esmolol (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol (500 micrograms/kg loading dose followed by 100 micrograms/kg/h infusion)
Study: 10680303
Drug: Diltiazem (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (0.15 mg/kg loading dose followed by 5 mg/h infusion)
Study: 1817959
Drug: Lamotrigine (100,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine (100, 200, and 300 mg/day, b.i.d. regimen)
Study: 29510699
Drug: Physically active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physically active academic lessons (2 x 45 minutes weekly for 10 months)
Study: 26933094
Drug: Oral opioid
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral opioid treatment
Study: 23190932
Drug: Functional exercise
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional exercise class (twice weekly for six weeks from week 12 to week 18 post surgery) supervised by a chartered Physiotherapist
Study: 20709000
Drug: Conventional TIV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional TIV (15 μg HA per strain)
Study: 16382423
Drug: Culturally adapted
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culturally adapted cognitive-behavior therapy (IT condition)
Study: 2375815
Drug: Intravenous fluids
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fluids (Ringer's Lactate and a solution of 56 mEq/L of Na)
Study: 199129
Drug: Fluphenazine decanoate
Normalized name: Fluphenazine Decanoate
DrugBank: Fluphenazine (DB00623)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluphenazine decanoate and oral fluphenazine
Study: 31449932
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (2 weeks of free nicotine patches and referral to an outpatient smoking-cessation program)
Study: 22332549
Drug: Fentanyl (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (100 microg initial dose, adjusted by 5 microg intervals) with 0.0625% W/V bupivacaine
Study: 19565824
Drug: Sodium levothyroxin
Normalized name: Levothyroxine Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium levothyroxin and standard hypotensive therapy with ACE inhibitors
Study: 17014518
Drug: Thrice‐weekly hemodialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice‐weekly hemodialysis (4 hr for 4 weeks)
Study: 15486373
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids (ICS) - triamcinolone acetonide (1200 microg daily)
Study: 3113599
Drug: Schwartz strain
Normalized name: Live attenuated measles virus (Schwartz strain)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schwartz strain live measles vaccine
Study: 10893282
Drug: Daily filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daily filgrastim (5 microg/kg/d)
Study: 1388334
Drug: Active medication
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active medication in patients without melancholia (76 patients)
Study: 3903068
Drug: Aspirin/dipyridamole combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin/dipyridamole combination
Study: 3550026
Drug: Conditioning therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conditioning therapy (n = 66)
Study: 23886632
Drug: Clopidogrel (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (300 mg loading dose followed by 75 mg/day)